ArticleBJC reports2025

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.

Peter Gallagher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.